Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China ...